業(yè)務(wù)咨詢(xún)
中國(guó)：
Email: marketing@www.msjidi.com
業(yè)務(wù)咨詢(xún)專(zhuān)線(xiàn)：400-780-8018
（僅限服務(wù)咨詢(xún)，其他事宜請(qǐng)撥打川沙總部電話(huà)）
川沙總部電話(huà): +86 (21) 5859-1500
海外：
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
Increased understanding of molecular pathways leads to the development of effective targeted therapies for the treatment of solid tumors.
Dabrafenib (DAB) undergoes oxidative metabolism via cytochrome P450 (CYP) 3A4 and CYP2C8 to form hydroxy-dabrafenib (OHD), an active metabolite, with a twofold higher potency than an inhibitor of mutant BRAF.
OHD (purity >99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.
Reference
David Balakirouchenane, et al. Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2021 Jan 30;193:113718. doi: 10.1016/j.jpba.2020.113718.
川沙總部
地址: 上海市浦東新區(qū)川大路585號(hào)
郵編: 201299
電話(huà): +86 (21) 5859-1500（總機(jī)）
傳真: +86 (21) 5859-6369
業(yè)務(wù)咨詢(xún)
中國(guó)：
Email: marketing@medicilon.com
業(yè)務(wù)咨詢(xún)專(zhuān)線(xiàn)：400-780-8018
（僅限服務(wù)咨詢(xún)，其他事宜請(qǐng)撥打川沙
總部電話(huà)）
海外：
Email:?marketing@medicilon.com
Tel: +1 (617) 888-9294(U.S.)
Tel: 0044 7790 816 954 (Europe)
Tel: +82 70-8269-5849 (Korea)
Tel: +81 80-4421-6898 (Japan)